Rankings
▼
Calendar
AMRX Q4 2023 Earnings — Amneal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
AMRX
Amneal Pharmaceuticals, Inc.
$4B
Q4 2023 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$617M
+1.2% YoY
Gross Profit
$225M
36.5% margin
Operating Income
$14M
2.3% margin
Net Income
-$99M
-16.0% margin
EPS (Diluted)
$-0.40
QoQ Revenue Growth
-0.5%
Cash Flow
Operating Cash Flow
$136M
Free Cash Flow
$104M
Stock-Based Comp.
$6M
Balance Sheet
Total Assets
$3.5B
Total Liabilities
$3.4B
Stockholders' Equity
$20M
Cash & Equivalents
$92M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$617M
$610M
+1.2%
Gross Profit
$225M
$215M
+4.7%
Operating Income
$14M
$36M
-60.6%
Net Income
-$99M
-$4M
-2176.7%
Revenue Segments
Generics Segment
$754M
100%
← FY 2023
All Quarters
Q1 2024 →